ABIN659065
antibody from antibodies-online
Targeting: RET
CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN659065 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Ret Proto-Oncogene (RET) antibody
- Antibody type
- Monoclonal
- Description
- Ascites
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgM
- Antibody clone number
- 188CT11-2-3
- Vial size
- 0.1 mL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles.
Submitted references A study of RET proto-oncogene polymorphisms in association with lung cancer risk in the Korean population.
Achalasia: will genetic studies provide insights?
The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Kim HK, Jung HY, Lim S, Sung JS, Whang YM, Jo U, Lee JE, Shin SW, Kim JS, Ryu JS, Kim YH
Anticancer research 2010 Sep;30(9):3621-7
Anticancer research 2010 Sep;30(9):3621-7
Achalasia: will genetic studies provide insights?
Gockel HR, Schumacher J, Gockel I, Lang H, Haaf T, Nöthen MM
Human genetics 2010 Oct;128(4):353-64
Human genetics 2010 Oct;128(4):353-64
The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Siqueira DR, Romitti M, da Rocha AP, Ceolin L, Meotti C, Estivalet A, Puñales MK, Maia AL
Endocrine-related cancer 2010 Dec;17(4):953-63
Endocrine-related cancer 2010 Dec;17(4):953-63
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC